ERNA — Ernexa Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 748592 ·
Last close
$3.28
Market Cap
$3.83M
52W High
$15.88
52W Low
$3.18
ADV30
933,457
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | 0 | -3,546,000 | -5,506,000 | 10,543,000 | 9,177,000 | 3,684,000 |
| Dec 2025 | 0 | 0 | -2,094,000 | -1,502,000 | 5,834,000 | 1,884,000 | 3,433,000 |
| Sep 2025 | 0 | 0 | -1,993,000 | -1,240,000 | 6,172,000 | 3,047,000 | 2,602,000 |
| Jun 2025 | 0 | 0 | -2,501,000 | -3,139,000 | 7,584,000 | 4,315,000 | 3,140,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,216,000
Investing CF
$-39,000
Financing CF
$14,514,000
CapEx
$-36,000
Dividends Paid
$8,000
Buybacks
—
EPS Diluted TTM
$-1636.75
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-245,636,000
Inventory
—
Receivables
$845,000
ST Investments
—
EBIT TTM
$-14,101,000
Pretax Income TTM
$-14,128,000
Interest Exp TTM
$5,169,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,319,000 | -14,084,000 | 5,834,000 | 3,433,000 | — | -7,017,000 |
| Dec 2024 | 582,000 | -17,250,000 | -44,539,000 | 5,269,000 | 3,568,000 | — | -15,836,000 |
| Dec 2023 | 68,000 | -20,675,000 | -21,668,000 | 49,132,000 | 46,899,000 | — | -20,408,000 |
| Dec 2022 | 0 | -26,947,000 | -24,579,000 | 22,279,000 | 10,172,000 | — | -20,976,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-9.60
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBIO | MUSTANG BIO, INC. | $3.84M | $0.57 | — |
| CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | $3.87M | $0.07 | — |
| ENSC | Ensysce Biosciences, Inc. | $3.89M | $0.25 | — |
| REVB | REVELATION BIOSCIENCES, INC. | $3.71M | $0.95 | — |
| RDHL | RedHill Biopharma Ltd. | $3.95M | $0.65 | — |
News headlines (Yahoo Finance, 1h cache)
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
2026-07-24 13:20 · Yahoo
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)
2026-07-15 13:43 · Yahoo
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
2026-07-15 11:50 · Yahoo
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
2026-07-14 13:01 · Yahoo
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
2026-06-25 13:15 · Yahoo
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
2026-06-17 12:47 · Yahoo
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
2026-06-09 12:41 · Yahoo
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
2026-05-27 12:11 · Yahoo
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
2026-05-20 14:45 · Yahoo
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
2026-05-20 12:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.